Skip to main content

12th March 2021

How will COVID vaccines be distributed across the globe?

Lauren Holland discusses the importance of the global vaccination scheme.
How will COVID vaccines be distributed across the globe?
U.S. Secretary of Defence @Flickr

The number of vaccinations are steadily increasing in the UK. To control the global risk of COVID-19, citizens of all countries must be vaccinated. The WHO-backed COVAX scheme is currently underway to provide equitable access of vaccines to less wealthy countries. Alongside the GAVI vaccine alliance and UNICEF, COVAX works with more than two-thirds of the world’s countries. It is attempting to end the pandemic, and provide free healthcare to the people that need it most.

The first countries to receive mass vaccinations through the COVAX scheme were Ghana and Ivory Coast. These began on the 1st of March. Beginning in Ghana, with the most vulnerable and frontline workers, as well as the President Nana Akufo-Addo, the Oxford-Astrazeneca vaccine began to be safely administered. 


The aim of Covax is to deliver 2 billion vaccines to 190 countries, including 92 poorer nations. This initiative is important for keeping the people of these countries safe and healthy, by providing immunity against this destructive virus. It also has huge benefits in reducing the global transmission of SARS-CoV-2. Wealthier countries will be much more able to negotiate and afford vaccine contracts. However, every country needs access to vaccines to protect everyone’s safety, including people in the UK.

If people are vaccinated quickly, the virus has less chance of spreading and mutating into potentially more dangerous versions. These versions may render the current vaccines ineffective. The scheme also provides a key level of security, even to the wealthier nations, as an ‘insurance policy’ – in case of a shortage on vaccines. 

Throughout history, many nations have lacked access to life-saving medicine. This includes that to help curb the spread of tuberculosis and HIV. The potential of this failure repeating itself is highlighted by the fact that the top 14% richest nations have already bought more than half of all of current promising vaccines.

COVAX is mostly funded through government aid, alongside some philanthropic donations. The US has pledged $4 billion towards the scheme after recently re-joining WHO. The UK has already committed £548 million.

WHO has estimated that global mass vaccinations improve the global economy by preventing the loss of $375 billion each month, so the cost to governments is likely to be a wise economic decision. 

No doubt met with challenges, COVAX is an ambitious scheme. However, a global effort to reduce the harm and spread of COVID-19 is necessary in restoring life as we know it and protecting the most vulnerable. 

More Coverage

Long COVID: Can improved sleep cure breathlessness?

A joint study led by The University of Manchester and Leicester has linked disturbed sleep to breathlessness in long COVID patients and proposes possible treatment solutions.

The power of stars: Manchester and its energy revolution

Manchester has long been making waves in the nuclear energy industry – find out how the scientific namesakes of university buildings set in motion a movement towards green energy.

First private Moon landing attempt fails

ispace’s new spacecraft made it within touching distance of the lunar surface, but a last-minute malfunction dashed their hopes of a successful moon landing

AI: Friend or foe?

What is the potential impact of artificial intelligence on the job market, and should students be worried about their future job prospects in light of AI advancements?